A Study of RPL554 in Patients With Cystic Fibrosis

Phase 2

Completed

• Conditions: Cystic Fibrosis
• Interventions: Drug: RPL554; Drug: Placebo

• Registration Number: NCT02919995
• Lead Sponsor: Verona Pharma plc

Brief Summary

This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-09-21
• Study First Submitted QC: 2016-09-27
• Study First Posted: 2016-09-30
• Study Start: 2017-02-08
• Primary Completion: 2017-11-03
• Study Completion: 2017-11-03
• Results First Submitted: 2018-12-07
• Results First Submitted QC: 2018-12-07
• Results First Posted: 2019-03-20
• Status Verified: 2019-05
• Last Update Submitted: 2024-04-22
• Last Update Posted: 2024-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• 1. Sign an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.

  2. Male or female aged ≥18 years at the time of informed consent. Females of childbearing potential must have been using a consistent and reliable form of contraception (see Appendix 1) from the last menses before the first study treatment administration, and must commit to continue to do so during the study and for 3 months after the last dose of study treatment.

  3. Have a 12-lead ECG recording at screening (Visit 1) and Visit 2 pre-dose showing the following:

  • Heart rate between 45 and 90 beats per minute

  • QT interval corrected for heart rate using Fridericia's formula (QTcF) interval ≤450 msec

  • QRS interval ≤120 msec

  • PR interval ≤220 msec

  • No clinically significant abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.

    5. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum weight of 40 kg.

    6. Patients with a genetic diagnosis of CF. 7. Spirometry at screening demonstrating an FEV1 ≥40% and ≤80% of predicted normal.

    7. Capable of withdrawing from long acting bronchodilators1 until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study treatment.

    8. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).

Exclusion Criteria

1. History of cirrhotic liver disease or portal hypertension.
2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or prior to randomisation (Visit 2).
3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).
4. Other non-CF related respiratory disorders: Patients with a current diagnosis of active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.
5. Previous lung resection or lung transplant.
6. History of, or reason to believe a patient has, drug or alcohol abuse within the past 3 years.
7. Received an experimental drug within 3 months or five half-lives, whichever is longer.
8. Patients with a history of chronic uncontrolled disease including, but not limited to, cardiovascular (including arrhythmias), endocrine, active hyperthyroidism, neurological, hepatic, gastrointestinal, renal, haematological, urological, immunological or ophthalmic diseases that the Investigator believes are clinically significant.
9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction, congestive heart failure, a history of unstable, or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.
10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to screening (Visit 1) or will not have fully recovered from surgery, or planned surgery through the end of the study.
11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus (MRSA), or Burkholderia species.
12. Use of immune-suppression; long term use of prednisolone ≥10 mg/day.
13. History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell).
14. Clinically significant abnormal values for safety laboratory tests (haematology, biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.
15. A disclosed history or one known to the Investigator, of significant non-compliance in previous investigational studies or with prescribed medications.
16. Requires oxygen therapy, even on an occasional basis.
17. Pregnancy or lactation (female subjects only).
18. Any other reason that the Investigator considers makes the patient unsuitable to participate. -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Higher Dose RPL554	RPL554	Single dose of inhaled 6 mg RPL554
Placebo	Placebo	Inhaled placebo dose
Lower dose RPL554	RPL554	Single dose of inhaled 1.5 mg RPL554

Primary Outcome Measures

Name	Time	Method
Half Life for Each Dose	Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose	Half life (t1/2) of RPL554
Maximum Plasma Concentration After Each Dose	Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose	Maximum plasma concentration (Cmax) after a single dose of RPL554
AUC by Dose	Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment	Area under the curve (AUC)
Time to Maximum Plasma Concentration After Each Dose	Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose	Time to maximum concentration (Tmax) after a single dose of RPL554

Secondary Outcome Measures

Name	Time	Method
FVC	Over 24 hours after treatment	Forced vital capacity (FVC) measured using spirometry
AUC FEV1(0-4h)	Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose	Area under the curve for FEV1 over 4 hours measured using spirometry
Laboratory Safety Tests 1	Screening and end of study	Biochemistry panel parameters
AUC FEV1(0-6h)	Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose	Area under the curve FEV1 over 6 hours measured using spirometry
ECG 1	Over 8 hours after treatment	Heart rate
Peak FEV1 for Each Treatment	Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment	Maximum Forced expired volume in one second (FEV1) measured using spirometry
AUC FEV1(0-8h)	pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose	Area under the curve for FEV1 over 8 hours measured using spirometry
Laboratory Safety Tests 3	Screening and end of study	Urinalysis measured by urine dipstick
Vital Signs 1	Over 8 hours after treatment	Pulse rate after 5 minutes supine
Breath Samples	8 and 24 hours after treatment	Exhaled breath pH
Laboratory Safety Tests 2	Screening and end of study	Haematology panel parameters
Vital Signs 2	Over 8 hours after treatment	Blood pressure after 5 minutes supine
ECG 2	Over 8 hours after treatment	QT interval

Trial Locations

Locations (1)

Papworth Hospital; 🇬🇧 Cambridge, United Kingdom